AEs With BCL-2i/PI3Ki

CE / CME

Multidisciplinary Perspectives on Managing Adverse Events With BCL-2 and PI3K Inhibitors in CLL

Pharmacists: 0.50 contact hour (0.05 CEUs)

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Nurses: 0.50 Nursing contact hour

Released: May 19, 2022

Expiration: May 18, 2023

Activity

Progress
1
Course Completed

In this focused activity, Nicole Lamanna, MD; Nichole Fisher, RN, BSN; and Anthony Perissinotti, PharmD, BCOP, review multidisciplinary best practices in identifying and managing key adverse events (AEs) commonly associated with BCL-2 and PI3K inhibitors in patients with chronic lymphocytic leukemia (CLL).

Clinical Care Options plans to measure the educational impact of this activity, and some questions in this activity will be asked twice: once prior to the discussion that informs the best choice and then again after that specific discussion. Your responses will be aggregated for analysis, but your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

If you are a practicing healthcare professional, how many patients with CLL do you provide care for in a typical month?

For patients with treatment-naive CLL who are beginning therapy with venetoclax, inpatient administration of the initial doses would be most appropriate if they show which of the following characteristics?